Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: L-cysteine toxicity

This article was originally published in The Tan Sheet

Executive Summary

L-cysteine toxicity: Tyson and Associates submits June 14 letter to FDA in support of a generally recognized as safe (GRAS) petition filed by Skymart Enterprises for L-cysteine. After conducting a literature review, Tyson concluded that "L-cysteine should essentially be taken under a doctor's supervision for children under 12 years old, and that it should not be removed from the marketplace. However, providing a better professional nutritional safe dose is recommended." Tyson previously conducted a literature search to support the safety of amino acids ("The Tan Sheet" Aug. 30, 1993, p. 16)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS084019

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel